ESMO Highlights

touchONCOLOGY joins Dr Scott Shepherd (London, UK), to discuss his presentation at ESMO 2021 on the CAPTURE study exploring adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients. To view Part One click here. Questions 1. How did immune responses relate to cancer stage and disease status? (00:18-03:26) 2. What are the implications of […]

touchONCOLOGY joins Dr Scott Shepherd (London, UK), to discuss his presentation at ESMO 2021 on the CAPTURE study exploring adaptive immunity to SARS-CoV-2 infection and vaccination in cancer patients. To view Part Two click here. Questions 1. What were the aims and design of the CAPTURE study? (00:18-02:25) 2. What were the study findings in […]

touchONCOLOGY joins Dr Domenica Lorusso (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (NCT03776812) Question Please summarise the randomized, open-label, phase II study presented at ESMO 2021 exploring progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant, a selective […]

touchONCOLOGY joins our Editor-in-Chief Prof Axel S Merseburger (University of Lübeck, Lübeck, Germany), to discuss the key data presented at the ESMO Congress 2021 in the field of advanced prostate cancer and the significant impact these advances have on clinical practice. Questions 1. What were the hottest topics and exciting new research from the ESMO […]

touchONCOLOGY joins Dr Julius Strauss (National Cancer Institute, National Institutes of Health, Bethesda, MD, USA), to discuss the long-term follow-up of patients with human papillomavirus–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1. Questions 1. What are the unmet needs in the treatment of human papillomavirus (HPV)-associated cancers? (00:15-01:37) 2. […]

touchONCOLOGY joins Prof Rahul Aggarwal (UCSF School of Medicine, San Francisco, CA, USA), to discuss the interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumour malignancies. Questions 1. Could you tell us a little about ARID1A alterations in solid tumours and potential therapeutic targets in […]

touchONCOLOGY joins Professor Guillaume Canaud (Necker–Enfants Malades Hospital, Paris, France), to discuss EPIK-P1, a retrospective chart review study of patients with PIK3CA-related overgrowth spectrum who have received alpelisib as part of a compassionate use programme. Questions 1. Could you tell us a little about PIK3CA-related Overgrowth Spectrum (PROS), the clinical manifestations and prognosis? (00:25-01:11) 2. […]

touchONCOLOGY joins Professor David S Hong (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) at ESMO 2021 to discuss the safety and activity of gavocabtagene autoleucel in a dose-escalation study in patients with refractory ovarian cancer, malignant mesothelioma, cholangiocarcinoma or non-small cell lung cancer. To view Part One, click here. Questions   […]

touchONCOLOGY joins Professor David S Hong (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) at ESMO 2021 to discuss the safety and activity of gavocabtagene autoleucel in a dose-escalation study in patients with refractory ovarian cancer, malignant mesothelioma, cholangiocarcinoma or non-small cell lung cancer. To view Part Two, click here. Questions 1. […]